Key Developments: Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

6.70EUR
11:36am EST
Change (% chg)

€1.61 (+31.63%)
Prev Close
€5.09
Open
€5.29
Day's High
€7.09
Day's Low
€5.29
Volume
3,306,681
Avg. Vol
193,949
52-wk High
€11.42
52-wk Low
€3.79

Search Stocks

Latest Key Developments (Source: Significant Developments)

Stentys clinical trial found treatment prevented amputation in 99 pct of cases
Wednesday, 28 Jan 2015 11:55am EST 

Stentys SA:Clinical trial found Stentys treatment prevented amputation in 99 percent of cases.Drug-eluting and self-expanding stent expected to be CE marked in H1 of 2015.  Full Article

Stentys signs exclusive agreement with Micell for distribution of its active stent
Monday, 3 Nov 2014 01:05pm EST 

Stentys SA:Signs exclusive agreement with Micell Technologies Inc for distribution of its active stent.Says agreement lasts 5 years.Says it will distribute coronary stent Mistent across world, except in United States, Canada, Japan, China, South Korea.  Full Article

Stentys SA's Sirolimus-Eluting Stent receives CE Marking
Monday, 27 Oct 2014 01:50pm EDT 

Stentys SA:Receives CE Marking for its Sirolimus-Eluting Stent (SES).CE Marking will allow the Company to market its SES in Europe immediately and, starting in 2015, in the many other countries where the company has commercial activity.  Full Article

Stentys wins tender which could be for more than 1,000 stents
Monday, 20 Oct 2014 12:34pm EDT 

Stentys SA:Wins SGH tender which could be for more than 1,000 stents.SGH tender is centralised purchase programme put in place by Gulf States' Council for Cooperation.SGH tender programme is renewed each year for 12 months.  Full Article

Stentys creates branch office in Dubai
Thursday, 25 Sep 2014 11:45am EDT 

Stentys SA:Announces creation of branch office in Dubai.  Full Article

Stentys announces positive results of Apposition III study
Tuesday, 16 Sep 2014 12:12pm EDT 

Stentys SA:Announces positive results of 1,000 patient Apposition III clinical study at two years after treatment of severe heart attack.At two years, MACE (defined as the composite of cardiac death, target-vessel myocardial infarction, emergent by-pass and clinically driven target lesion revascularization), was 11.2 pct compared to 9.3 pct at one year.Cardiac death at two years was 2.3 pct compared to 2.0 pct at one year.  Full Article

Stentys signs first distribution agreements in South America
Wednesday, 9 Jul 2014 11:46am EDT 

Stentys SA:Signs first distribution contracts in Argentina, Chile and Colombia.Contracts signed within company strategy to expand commercial presence into Latin American coronary stent market.  Full Article

Stentys SA completes acquisition of Cappella Peel Away Inc
Thursday, 12 Jun 2014 01:00pm EDT 

Stentys SA:Says it presented the final terms of the acquisition of Cappella Peel Away Inc. and of its assets relating to a stent delivery system for a total amount of 1 million euro in stock and cash.  Full Article

Stentys SA to acquire Stent Delivery Technology
Wednesday, 4 Jun 2014 11:45am EDT 

Stentys SA:Signs acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a stent delivery system.Financial terms were not disclosed.  Full Article

Stentys SA presented final results from APPOSITION IV study
Tuesday, 20 May 2014 07:15am EDT 

Stentys SA:Presented final results from APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during Hotline session at EuroPCR conference in Paris.APPOSITION IV enrolled 152 patients experiencing ST-elevation myocardial infarction (STEMI) and was first clinical trial to evaluate novel Self-Apposing sirolimus-eluting stent, which was compared to Medtronic`s Resolute zotarolimus-eluting stent at two different time points, 4 and 9 months.Evaluation was based on two imaging modalities, Quantitative Coronary Angiography (QCA) to measure difference in artery diameters between implantation and follow-up, and Optical Coherence Tomography (OCT).Results confirm that arteries with STENTYS SES healed faster than with balloon-expandable drug-eluting stents.At 9 months, STENTYS SES showed no reduction in artery lumen diameter (Late Lumen Loss of 0.04mm ± 0.43 under QCA) with near perfect arterial healing (99 pct covered struts at 9 months under OCT), demonstrating stent efficacy and safety.  Full Article

BRIEF-Stentys clinical trial found treatment prevented amputation in 99 pct of cases

* Clinical trial found Stentys treatment prevented amputation in 99 percent of cases

Search Stocks